MMB specializes in clinical manufacturing of intermediates and final products used in viral vaccines and gene therapies. Through the use of a state-of-the-art facility, MMB utilizes a variety of bioreactors and purification processes to produce high titer, high purity product. Bulk drug can be filled in the company’s ISO 6 (Class 1000) cleanroom and stored in its controlled GMP storage area.